alexa
Reach Us +44-1904-929220
The Future of Melanoma Therapy is the Combination Approach | OMICS International | Abstract
ISSN-2155-9929

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Editorial

The Future of Melanoma Therapy is the Combination Approach

Paolo Antonio ASCIERTO*

Unit of Medical Oncology and Innovative Therapies, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione “G. Pascale”, Napoli, Italy

*Corresponding Author:
Paolo Antonio Ascierto
Unit of Medical Oncology and Innovative Therapies
Istituto Nazionale per lo Studio e la Cura dei Tumori
Fondazione “G. Pascale”, Napoli, Italy
E-mail: [email protected]

Received Date: August 24, 2011; Accepted Date: August 05, 2011; Published Date: August 07, 2011

Citation: Ascierto PA (2011) The Future of Melanoma Therapy is the Combination Approach. J Mol Biomark Diagn 2:102e. doi:10.4172/2155-9929.1000e102

Copyright: © 2011 ASCIERTO PA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Abstract

From a historical point of view, treatment of neoplastic disease can be considered one of the clearest example of the importance of combination strategies. In fact, a combination of surgery, radiotherapy and chemotherapy, is the best approach for the treatment of certain cancers such as breast cancer, ovarian and head and neck cancer. However, not only cancer may benefit from combination therapy. Tubercolosis is a classical example of this concept [1]. After the discovery of Streptomycin in 1944, a new era for the treatment of tubercolosis dawned with further detection of Isoniazid, the first oral mycobactericidal drug in 1952 and Rifamycins in 1957. Sanatoria closed and truly effective public health measures became possible. Treatment was also increasingly expanded to include those with latent tuberculous infections. Furthermore, the introduction of Rifampicin in 1970 revolutionized the treatment of tuberculosis as, with its use in the context of combination strategies, the therapy of this infectious disease changed. In fact, use of antituberculosis drugs in monotherapy, including those of first choice, is strictly proscribed, since it might be easy to select spontaneously resistant germs. For this reason, drug regimens include associations of 3 or more drugs, variously alternated in relation to the clinical and developmental stages of tuberculosis (Table 1). Another aim of using drugs in combination was to eliminate bacterial subpopulations in various stages of metabolic activity and at different locations.

Recommended Conferences

15th Global Biomarkers and Clinical Research Summit

Vienna, Austria

2nd International Conference on Biomarkers and Cancer Targets

Capetown, South Africa
Share This Page
Top